In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2
(B2A2) transcript is prevalent

J 2020

In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent

BACCARANI, M., I. IACOBUCCI, S. CHIARETTI, R. FOA, P. BALASUBRAMANIAN et. al.

Basic information

Original name

In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent

Authors

BACCARANI, M. (guarantor), I. IACOBUCCI, S. CHIARETTI, R. FOA, P. BALASUBRAMANIAN, E. PAIETTA, L. FORONI, S. JEROMIN, B. IZZO, O. SPINELLI, N. VARMA, S. MENIF, C. TERRAGNA, T. SETH, A. BIDET, D. CORIU, F. LUNGHI, Jiří MAYER (203 Czech Republic, belonging to the institution), B. SCAPPINI, S. LANGABEER, J. MAIER, E. BURT, A. CANDONI, F. ALBANO, M. LUPPI, I. ZUPAN, T. LION, R. ZADRO, F. DI RAIMONDO, B. POOPAK, G. REGE-CAMBRIN, M. ANNUNZIATA, A. AYALA, V. SALINAS-VIEDMA, A. INES PADO, B. MILNER, S. GALIMBERTI, J. JANSSEN, V. POLLI, L. COMBA, B. BORSELLINO, O. ANNIBALI, M. CRUGNOLA and F. PASSAMONTI

Edition

Leukemia, London, Nature Publishing Group, 2020, 0887-6924

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 11.528

RIV identification code

RIV/00216224:14110/20:00118153

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1038/s41375-019-0591-9

UT WoS

000519468700024

Keywords in English

acute lymphoblastic leukemia

Abstract

V originále

Philadelphia-chromosome positive (Ph+), BCR-ABL1+ acute lymphoblastic leukemia (ALL) is a distinct entity that is characterized by specific genomic alterations, low sensitivity to chemotherapy, unstable responsiveness to tyrosine kinase inhibitors (TKIs), and a poor prognosis.

Citovat

BACCARANI, M., I. IACOBUCCI, S. CHIARETTI, R. FOA, P. BALASUBRAMANIAN, E. PAIETTA, L. FORONI, S. JEROMIN, B. IZZO, O. SPINELLI, N. VARMA, S. MENIF, C. TERRAGNA, T. SETH, A. BIDET, D. CORIU, F. LUNGHI, Jiří MAYER, B. SCAPPINI, S. LANGABEER, J. MAIER, E. BURT, A. CANDONI, F. ALBANO, M. LUPPI, I. ZUPAN, T. LION, R. ZADRO, F. DI RAIMONDO, B. POOPAK, G. REGE-CAMBRIN, M. ANNUNZIATA, A. AYALA, V. SALINAS-VIEDMA, A. INES PADO, B. MILNER, S. GALIMBERTI, J. JANSSEN, V. POLLI, L. COMBA, B. BORSELLINO, O. ANNIBALI, M. CRUGNOLA and F. PASSAMONTI. In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. Leukemia. London: Nature Publishing Group, 2020, vol. 34, No 3, p. 929-931. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-019-0591-9.

@article{1740658,
   author = {Baccarani, M. and Iacobucci, I. and Chiaretti, S. and Foa, R. and Balasubramanian, P. and Paietta, E. and Foroni, L. and Jeromin, S. and Izzo, B. and Spinelli, O. and Varma, N. and Menif, S. and Terragna, C. and Seth, T. and Bidet, A. and Coriu, D. and Lunghi, F. and Mayer, Jiří and Scappini, B. and Langabeer, S. and Maier, J. and Burt, E. and Candoni, A. and Albano, F. and Luppi, M. and Zupan, I. and Lion, T. and Zadro, R. and di Raimondo, F. and Poopak, B. and RegeandCambrin, G. and Annunziata, M. and Ayala, A. and SalinasandViedma, V. and Ines Pado, A. and Milner, B. and Galimberti, S. and Janssen, J. and Polli, V. and Comba, L. and Borsellino, B. and Annibali, O. and Crugnola, M. and Passamonti, F.},
   article_location = {London},
   article_number = {3},
   doi = {http://dx.doi.org/10.1038/s41375-019-0591-9},
   keywords = {acute lymphoblastic leukemia},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent},
   url = {https://www.nature.com/articles/s41375-019-0591-9},
   volume = {34},
   year = {2020}
}

TY  - JOUR
ID  - 1740658
AU  - Baccarani, M. - Iacobucci, I. - Chiaretti, S. - Foa, R. - Balasubramanian, P. - Paietta, E. - Foroni, L. - Jeromin, S. - Izzo, B. - Spinelli, O. - Varma, N. - Menif, S. - Terragna, C. - Seth, T. - Bidet, A. - Coriu, D. - Lunghi, F. - Mayer, Jiří - Scappini, B. - Langabeer, S. - Maier, J. - Burt, E. - Candoni, A. - Albano, F. - Luppi, M. - Zupan, I. - Lion, T. - Zadro, R. - di Raimondo, F. - Poopak, B. - Rege-Cambrin, G. - Annunziata, M. - Ayala, A. - Salinas-Viedma, V. - Ines Pado, A. - Milner, B. - Galimberti, S. - Janssen, J. - Polli, V. - Comba, L. - Borsellino, B. - Annibali, O. - Crugnola, M. - Passamonti, F.
PY  - 2020
TI  - In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent
JF  - Leukemia
VL  - 34
IS  - 3
SP  - 929-931
EP  - 929-931
PB  - Nature Publishing Group
SN  - 08876924
KW  - acute lymphoblastic leukemia
UR  - https://www.nature.com/articles/s41375-019-0591-9
L2  - https://www.nature.com/articles/s41375-019-0591-9
N2  - Philadelphia-chromosome positive (Ph+), BCR-ABL1+ acute lymphoblastic leukemia (ALL) is a distinct entity that is characterized by specific genomic alterations, low sensitivity to chemotherapy, unstable responsiveness to tyrosine kinase inhibitors (TKIs), and a poor prognosis.
ER  -

BACCARANI, M., I. IACOBUCCI, S. CHIARETTI, R. FOA, P. BALASUBRAMANIAN, E. PAIETTA, L. FORONI, S. JEROMIN, B. IZZO, O. SPINELLI, N. VARMA, S. MENIF, C. TERRAGNA, T. SETH, A. BIDET, D. CORIU, F. LUNGHI, Jiří MAYER, B. SCAPPINI, S. LANGABEER, J. MAIER, E. BURT, A. CANDONI, F. ALBANO, M. LUPPI, I. ZUPAN, T. LION, R. ZADRO, F. DI RAIMONDO, B. POOPAK, G. REGE-CAMBRIN, M. ANNUNZIATA, A. AYALA, V. SALINAS-VIEDMA, A. INES PADO, B. MILNER, S. GALIMBERTI, J. JANSSEN, V. POLLI, L. COMBA, B. BORSELLINO, O. ANNIBALI, M. CRUGNOLA and F. PASSAMONTI. In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. \textit{Leukemia}. London: Nature Publishing Group, 2020, vol.~34, No~3, p.~929-931. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-019-0591-9.

Detailed Information on Publication Record